Clinical Trial Results:
Prevention of breast cancer-related lymphedema with tacrolimus
Summary
|
|
EudraCT number |
2018-003416-50 |
Trial protocol |
DK |
Global end of trial date |
22 Nov 2022
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
21 Oct 2023
|
First version publication date |
21 Oct 2023
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
2018-BCRL-TACRO
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT04390685 | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
Odense university Hospital
|
||
Sponsor organisation address |
J.B. Winsløws vej 4, Odense, Denmark, 5000
|
||
Public contact |
Dept. of Plastic Surgery, Odense University Hospital, 0045 65412436 , jens.sorensen@rsyd.dk
|
||
Scientific contact |
Dept. of Plastic Surgery, Odense University Hospital, 0045 65412436 , jens.sorensen@rsyd.dk
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Interim
|
||
Date of interim/final analysis |
28 Sep 2023
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
22 Nov 2022
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
22 Nov 2022
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
The study will evaluate the feasibility of tacrolimus ointment in preventing lymphedema after breast cancer treatment.
|
||
Protection of trial subjects |
The protection of clinical trial subjects is consistent with the principles set out in the Declaration of Helsinki
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
29 Feb 2020
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
Yes
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Denmark: 61
|
||
Worldwide total number of subjects |
61
|
||
EEA total number of subjects |
61
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
49
|
||
From 65 to 84 years |
12
|
||
85 years and over |
0
|
|
|||||||||||||||||||||||||||||||
Recruitment
|
|||||||||||||||||||||||||||||||
Recruitment details |
Participants were recruited at Odense University Hospital, Lillebælt Hospital Vejle, and Hospital of Southwest Jutland in Esbjerg from February 2020 to June 2022. Patients included at Odense University hospital were assigned to the treatment group, and patients included at Vejle and Esbjerg were allocated to the control group. | ||||||||||||||||||||||||||||||
Pre-assignment
|
|||||||||||||||||||||||||||||||
Screening details |
Inclusion took place 1-4 days prior to the scheduled axillary lymph node dissection surgery. During the course of breast cancer treatment, potential participants were screened for eligibility criteria at the outpatient clinic for each participating study site by clinical staff. | ||||||||||||||||||||||||||||||
Period 1
|
|||||||||||||||||||||||||||||||
Period 1 title |
Overall period
|
||||||||||||||||||||||||||||||
Is this the baseline period? |
Yes | ||||||||||||||||||||||||||||||
Allocation method |
Non-randomised - controlled
|
||||||||||||||||||||||||||||||
Blinding used |
Not blinded | ||||||||||||||||||||||||||||||
Arms
|
|||||||||||||||||||||||||||||||
Are arms mutually exclusive |
Yes
|
||||||||||||||||||||||||||||||
Arm title
|
Invervention | ||||||||||||||||||||||||||||||
Arm description |
- | ||||||||||||||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||||||||||||||
Investigational medicinal product name |
Tacrolimus (0.1 % tacrolimus)
|
||||||||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||||||||
Other name |
|||||||||||||||||||||||||||||||
Pharmaceutical forms |
Ointment
|
||||||||||||||||||||||||||||||
Routes of administration |
Cutaneous use
|
||||||||||||||||||||||||||||||
Dosage and administration details |
1 thin layer on the axilla, arm and hand daily for 12 months
|
||||||||||||||||||||||||||||||
Arm title
|
Control | ||||||||||||||||||||||||||||||
Arm description |
Control group not recieving any treatment | ||||||||||||||||||||||||||||||
Arm type |
No intervention | ||||||||||||||||||||||||||||||
Investigational medicinal product name |
No investigational medicinal product assigned in this arm
|
||||||||||||||||||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Overall period
|
||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | ||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Invervention
|
||
Reporting group description |
- | ||
Reporting group title |
Control
|
||
Reporting group description |
Control group not recieving any treatment | ||
Subject analysis set title |
Endpoints
|
||
Subject analysis set type |
Per protocol | ||
Subject analysis set description |
Data was analyzed per protocol.
|
|
||||||||||||||||
End point title |
Lymphedema diagnosis | |||||||||||||||
End point description |
||||||||||||||||
End point type |
Primary
|
|||||||||||||||
End point timeframe |
Observed at 12 months follow up
|
|||||||||||||||
|
||||||||||||||||
Statistical analysis title |
Paired t-test | |||||||||||||||
Comparison groups |
Invervention v Control
|
|||||||||||||||
Number of subjects included in analysis |
55
|
|||||||||||||||
Analysis specification |
Pre-specified
|
|||||||||||||||
Analysis type |
other | |||||||||||||||
P-value |
> 0.05 | |||||||||||||||
Method |
t-test, 2-sided | |||||||||||||||
Confidence interval |
|
||||||||||||||||
End point title |
Lymphedema criteria met? | |||||||||||||||
End point description |
Was a change of a least 10% seen in the arm at-risk
|
|||||||||||||||
End point type |
Secondary
|
|||||||||||||||
End point timeframe |
baseline to 12 months
|
|||||||||||||||
|
||||||||||||||||
Statistical analysis title |
Paired t-test | |||||||||||||||
Comparison groups |
Invervention v Control
|
|||||||||||||||
Number of subjects included in analysis |
55
|
|||||||||||||||
Analysis specification |
Pre-specified
|
|||||||||||||||
Analysis type |
other | |||||||||||||||
P-value |
> 0.05 | |||||||||||||||
Method |
t-test, 2-sided | |||||||||||||||
Confidence interval |
|
|||||||||||||
End point title |
Change in arm volume difference | ||||||||||||
End point description |
Change in difference in arm volume for each patient fra baseline to 12 months
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Baseline to 12 months
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Paired t-test | ||||||||||||
Comparison groups |
Invervention v Control
|
||||||||||||
Number of subjects included in analysis |
55
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
equivalence | ||||||||||||
P-value |
> 0.05 | ||||||||||||
Method |
t-test, 2-sided | ||||||||||||
Confidence interval |
|
|||||||||||||
End point title |
LYMPH ICF | ||||||||||||
End point description |
Change in LYMPH ICF scores
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
baseline to 12 months
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Paired t-test | ||||||||||||
Comparison groups |
Invervention v Control
|
||||||||||||
Number of subjects included in analysis |
55
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
equivalence | ||||||||||||
P-value |
> 0.05 | ||||||||||||
Method |
t-test, 2-sided | ||||||||||||
Confidence interval |
|
|||||||||||||
End point title |
DASH | ||||||||||||
End point description |
change in DASH scores
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Baseline to 12 months
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Paired t-test | ||||||||||||
Comparison groups |
Invervention v Control
|
||||||||||||
Number of subjects included in analysis |
55
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
equivalence | ||||||||||||
P-value |
> 0.05 | ||||||||||||
Method |
t-test, 2-sided | ||||||||||||
Confidence interval |
|
|||||||||
End point title |
L-Dex [1] | ||||||||
End point description |
Any assessed for the intervention group
|
||||||||
End point type |
Secondary
|
||||||||
End point timeframe |
baseline to 12 months
|
||||||||
Notes [1] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Only the intervention group was assessed with l-dex |
|||||||||
|
|||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||
Adverse events information
|
|||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
0-12 months
|
||||||||||||||||||||||||||||||
Adverse event reporting additional description |
Data collected throughout the study
|
||||||||||||||||||||||||||||||
Assessment type |
Systematic | ||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||||||||||
Dictionary name |
none | ||||||||||||||||||||||||||||||
Dictionary version |
0
|
||||||||||||||||||||||||||||||
Reporting groups
|
|||||||||||||||||||||||||||||||
Reporting group title |
intervention
|
||||||||||||||||||||||||||||||
Reporting group description |
The intervention group was instructed to apply a thin layer of 0.1% tacrolimus ointment to the arm, hand, and axilla for a period. of 12 months starting from the day after surgery. | ||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 5% | |||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? No | |||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported |